Noninferiority seen in three-year metastasis-free survival for men with locally advanced prostate cancer. (HealthDay News) — For men with locally advanced prostate cancer, transdermal estradiol (tE2) ...

The researchers found that the observed 3-year metastasis-free survival was 87.1 and 85.9% with transdermal estradiol patches and luteinizing hormone-releasing hormone agonists, respectively.

FRIDAY, April 10, 2026 (HealthDay News) -- For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing hormone-releasing hormone (LHRH) agonists ...

As consumer attention around transdermal wellness patches grows in 2026, interest has also expanded around ingredient visibility, product variety, and policy transparency across the category. This ...

For women in perimenopause and menopause, hormone therapy can be the difference between waking up every night at 3 a.m., having sweat through yet another pajama top, or getting a good night’s rest and ...

If you’ve tried to fill an estrogen patch prescription recently and come up empty, you’re not imagining things. Patches have become genuinely hard to find across the country, and the reasons behind it ...

Add Task & Purpose (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is ...

Many women across the country are struggling to get their hands on estrogen patches after the FDA removed black box warning labels on many hormone therapy drugs. The removal was initially celebrated, ...

Game balances simple mechanics with increasing difficulty throughout the week. LinkedIn Games sees millions of daily players with 86% returning the next day. Patches inspired by the Japanese puzzle ...